Type 1 Diabetes Score Misses Remissions in Youth with Obesity
Standard screening cutoffs fail to detect partial remission in children with overweight or obesity because higher body weight alters insulin requirements.
Standard Screening Fails to Identify Youth in Partial Remission
A widely used diabetes calculation misses more than half of partial remissions in youth with overweight or obesity. Baylor College of Medicine researchers published the findings in the journal Diabetes Care. The study evaluated insulin dose-adjusted hemoglobin A1c (IDAA1c) against laboratory reference standards.
The data covered 422 participants. All subjects had enrolled in the SEARCH for Diabetes in Youth Study within one year of diagnosis. The team found that the standard threshold leaves many cases undetected.
Residual Insulin Production and the Honeymoon Phase
Following a type 1 diabetes diagnosis and the start of insulin therapy, some individuals continue producing insulin for a limited time. Clinicians refer to this temporary window as partial remission or the honeymoon phase. This phase helps stabilize daily blood glucose management.
Ongoing natural insulin secretion provides distinct clinical advantages. Patients experience fewer severe low blood sugar episodes and have a lower risk of long-term diabetes complications. Accurately tracking this phase allows doctors to monitor remaining beta-cell activity.
Limitations of Clinical Screening Tools
The stimulated C-peptide test serves as the reference standard for measuring natural insulin production. This test requires multiple blood draws over several hours, making it impractical for routine clinic visits. Most medical centers rely on calculated scores instead.
The IDAA1c calculation combines hemoglobin A1c with daily insulin dose per kilogram of body weight. An IDAA1c score of nine or lower traditionally indicates partial remission. However, researchers originally established that cutoff in Northern European cohorts with lower average body mass index values.
Accuracy Drops in Youth with Overweight or Obesity
Across the entire study group, the cutoff score of nine correctly identified 61 percent of youth in partial remission. It also correctly identified 79 percent of youth who were not in remission.
Performance dropped sharply among children and adolescents with overweight or obesity. The standard threshold caught only 45 percent of those individuals in remission confirmed by C-peptide values. The calculation missed the remaining 55 percent, falsely indicating that their honeymoon phase had concluded.
Tradeoffs in Adjusting Diagnostic Thresholds
The investigators examined whether raising the cutoff score to 11.6 would improve detection. While this higher number identified more individuals in remission, it also caused an unacceptable increase in false-positive results. Adjusting the cutoff failed to produce an ideal clinical benchmark.
Overweight and obesity increase insulin resistance, which naturally raises baseline insulin requirements regardless of residual beta-cell function. Patients and families should talk to a pediatric endocrinologist about how weight and insulin resistance affect individual lab assessments.
What to Look For in a Body-Composition Scale
A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.


Related Articles
Study Finds Widening Disparities in Weight-Loss GLP-1 Access
A study of 512,389 commercially insured adults found that access gaps for weight-loss GLP-1...
Read article MetabolismGlucose-Powered Implant Improves Blood Sugar in Animal Study
A study in Nature reports on NeuroAxis, an experimental implant powered by glucose that...
Read article MetabolismNatural Peptide Protects Retinal Cells in Laboratory Diabetes Model
A study in Biomedicine & Pharmacotherapy shows the Annexin A1 peptide Ac2-26 shields retinal...
Read article MetabolismGenetic Markers of Young-Onset Type 2 Diabetes Identified in Study
A genome-wide study identified three genetic markers of young-onset type 2 diabetes that impair...
Read articleWant medical weight loss instead of another diet?
Opt Health prescribes and monitors GLP-1 therapy against real labs — insulin, A1C, lipids, thyroid, hormones — so the plan fits your physiology rather than a generic protocol. Medication ships to your door.
See Opt Health's weight-loss program →Topic updates
Get the weekly metabolic health roundup
Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.
Understand Your Health Better
Our free assessment maps your symptoms to the most relevant guides, tools, and product recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Affiliate disclosure: The Metabolic Journal is reader-supported. Some links above are affiliate or referral links and we may earn a commission at no extra cost to you. Products are chosen on the merits; commissions never influence what we recommend. This is general information, not medical advice — talk to your clinician before acting.